Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 8, 2022--
The "Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor.
The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy.
Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.
Market Dynamics
Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC).
Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S.
Key features of the study:
Detailed Segmentation:
Global Nephroblastoma Treatment Market, By Type:
Global Nephroblastoma Treatment Market, By Drug Type:
Global Nephroblastoma Treatment Market, By Distribution Channel:
Global Nephroblastoma Treatment Market, By Region:
Company Profiles
Key Topics Covered:
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Nephroblastoma Treatment Market- COVID-19 Impact Analysis
5. Global Nephroblastoma Treatment Market, By Type, 2017 - 2030, (US$ Million)
6. Global Nephroblastoma Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)
7. Global Nephroblastoma Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)
8. Global Nephroblastoma Treatment Market, By Region, 2017 - 2030, (US$ Million)
9. Competitive Landscape
10. Section
For more information about this report visit https://www.researchandmarkets.com/r/l33dky
View source version on businesswire.com:https://www.businesswire.com/news/home/20221108005887/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/08/2022 10:58 AM/DISC: 11/08/2022 10:58 AM
http://www.businesswire.com/news/home/20221108005887/en